Biotech News

Amgen wins FDA approval for late-stage oncology treatment

Amgen Inc. (AMGN)amgen.comFDA / regulatory

Amgen (AMGN) appears in the live feed after an FDA catalyst that can change the stock's tone quickly.

The source domain is amgen.com. BioPharmSignal keeps the ticker, timestamp, and source together so readers can move from signal to source without leaving the flow.

The original release is available below in a new tab so you can continue into the full source when needed.

Related news

REGNRegeneron Pharmaceuticals2026-11-18 23:03 EST

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

REGNRegeneron Pharmaceuticals2026-10-16 11:00 EST

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

IDYAIDEAYA Biosciences2026-11-16 21:05 EST

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

TEVATeva Pharmaceutical Industries2026-11-16 13:00 EST

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

JNJJohnson & Johnson2026-10-16 10:31 EST

CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

GSKGSK plc2026-10-20 17:42 EST

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)

LEGNLegend Biotech Corporation2026-10-15 12:00 EST

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

Amgen Inc.

Large-Cap Biotechnology Company Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes medicines using human biology, advanced genetics, and protein engineering. Its portfolio spans general medicine, cardiovascular disease, rare disease, inflammation, hematology, and oncology, supported by...

Recent company news

Stock data

Close
438.82 USD
Market cap
177.16B USD
Exchange
NASDAQ
Sector
Generics, Biopharma, Oncology, Immunotherapy
Location
Thousand Oaks, California